Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
المؤلفون المشاركون
Liu, Chien-Ming
Chiu, Kuo-Liang
Chen, Tzu-Sheng
Chang, Shang-Miao
Yang, Shu-Yun
Chen, Li-Hsiou
Ni, Yung-Lun
Sher, Yuh-Pyng
Yu, Sung-Liang
Ma, Wen-Lung
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-01-26
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Introduction.
Epidermal growth factor receptor (EGFR) mutations are known as oncogene driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine kinase inhibitor Gefitinib.
Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adenocarcinoma.
We evaluated the relationship between the two receptors and the potential therapeutic benefit with Gefitinib and Tamoxifen.
Methods.
We assessed the association between EGFR mutations as well as ERα/β expression/location and overall survival in a cohort of 55 patients with LAC from a single hospital.
PC9 (EGFR exon 19 deletion mutant; Gefitinib-vulnerable cells) and A549 (EGFR wild type; Gefitinib-resistant cells) cancer cells were used to evaluate the in vitro therapeutic benefits of combining Gefitinib and Tamoxifen.
Results.
We found that the cytosolic but not the nuclear expression of ERβ was associated with better OS in LAC tumors but not associated with EGFR mutation.
The in vitro study showed that combined Gefitinib and Tamoxifen resulted in increased apoptosis and cytosolic expression of ERβ.
In addition, combining both medications resulted in reduced cell growth and increased the cytotoxic effect of Gefitinib.
Conclusion.
Tamoxifen enhanced advanced LAC cytotoxic effect induced by Gefitinib by arresting ERβ in cytosol.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Liu, Chien-Ming& Chiu, Kuo-Liang& Chen, Tzu-Sheng& Chang, Shang-Miao& Yang, Shu-Yun& Chen, Li-Hsiou…[et al.]. 2015. Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma. BioMed Research International،Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1056251
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Liu, Chien-Ming…[et al.]. Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma. BioMed Research International No. 2015 (2015), pp.1-11.
https://search.emarefa.net/detail/BIM-1056251
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Liu, Chien-Ming& Chiu, Kuo-Liang& Chen, Tzu-Sheng& Chang, Shang-Miao& Yang, Shu-Yun& Chen, Li-Hsiou…[et al.]. Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1056251
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1056251
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر